Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Dec 5;11(12):1950. doi: 10.3390/cancers11121950

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2019 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Relative risk (RR) of “pyrexia” adverse events; all grades. Combined RR of all studies was 1.27 (95% CI 0.59–2.73), showing no significant difference in risk of pyrexia between combination and monotherapy. Encorafenib plus binimetinib in the Dummer study had an RR of 0.65 (95% CI 0.45–0.95), revealing a significantly smaller risk of pyrexia as compare to monotherapy. Dabrafenib plus trametinib in the Robert study had an RR of 2.51 (95% CI 2.00–3.15), revealing a significantly higher risk of pyrexia in the combination group. Vemurafenib and cobimetinib compared to vemurafenib in the Ascierto study did not show and significant difference in risk of pyrexia between groups.